American Journal of Cancer Research and Reviews


Case Report of American Journal of Cancer Research and Reviews MANDIBULAR OSTEONECROSIS RELATED TO THE USE OF BISPHOSPHONATE IN ONCOLOGY: CASE REPORT Anna Danielly Almeida do Nascimento¹ *, Beatriz Santos Borges¹, Cristianne de Barros Santos¹, Laís Azevedo Lins de Holanda¹, Aurora Karla de Lacerda Vidal¹.  ¹ Instituto de Ciências Biológicas e Centro de Oncologia do Hospital Universitário Oswaldo Cruz da Universidade de Pernambuco (ICB/CEON/HUOC/UPE) Objective: Evidence that the inflammation, infection, necrosis and pain present in osteonecrosis may be related to the use of bisphosphonates in oncology. Methods: It’s a clinical case report of mandibular osteonecrosis, female, 73 years old, treated and under medical and multiprofessional oncology follow-up, at the Oncology Center of the Oswaldo Cruz University Hospital of the University of Pernambuco, for control of invasive ductal carcinoma of breast (Anatomopathological115134) and bilateral bone and lung metastases. Currently, using Faslodex 250mg - 02 ampoules and Zometa (bisphosphonate). Results: With a extraction history performed during the use of bisphosphonate, and with a removable upper and lower total dental prosthesis, attended the Dental Service of aforementioned Oncology Center, presenting bone exposure in the anterior mandible region and complaining of local pain. After clinical and radiographic evaluation, the diagnosis of osteonecrosis was confirmed, characterized by necrosis, pain and bone infection. Considering the mandibular clinical and radiographic condition, and the oncological condition, the Oral Care’s Standard Operational Protocol for Osteonecrosis was initiated, adapted from the Dentistry Service of the National Cancer Institute, but without the Low Power Laser. After 4 months, clinical improvement was noted and the absence of painful symptoms was reported. In addition, it follows the Oral Care Protocol and is being followed up at the aforementioned specialized Service. Conclusion: Invasive surgical procedures and local trauma should be avoided during therapy with bisphosphonates, as they can favor the development of osteonecrosis, in ...

Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives

Review Article of American Journal of Cancer Research and Reviews Giant Cell Tumor of Bone, current treatments, and potential therapeutic alternatives Estrada-Villaseñor E.,1 Meneses A.,2 Valdés-Flores M.,3 Coutiño-Alcaraz JM.,4 Linares-González LM.,5 Olivos Meza A.,6 Ostoa-Saloma P.,7 Delgado Cedillo EA.,8 Landa Solís C.9 1National Institute of Rehabilitation. Pathology Service. Mexico City, México. 2National Cancer Institute. Managing Director. Mexico City, Mexico. 3National Institute of Rehabilitation. Assistant Manager Clinical Research in genetic service. Mexico City, México. 4National Institute of Rehabilitation. Pathology Service. Mexico City, Mexico. 5National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 6National Institute of Rehabilitation. Arthroscopy Service. Mexico City, México. 7Postgraduate degree in Biological Sciences, National Autonomous University of Mexico, University City, Mexico, Mexico City. 8National Institute of Rehabilitation. Bone Tumors Service. Mexico City, Mexico. 9National Institute of Rehabilitation. Tissue Engineering and Cell Therapy Unit. Mexico City, Mexico. Giant cell tumor of bone (GCTB) is a primary bone tumor, locally aggressive. For many, a GCTB is considered a tumor with an unpredictable behavior, particularly regarding recurrences, pulmonary implants, and the possibility of primary malignancy. In terms of risk of recurrence, it is known that it is associated with the type of treatment used initially for the GCTB. The greater the number or recurrences, the greater the risk of pulmonary implants, and the greater the risk of malignant degeneration. Therefore, much of the prognosis of this tumor could be related to the type of initial treatment. Hence the importance of the treatment theme. This review includes a comparison between the various modalities for treatment in GCTB, considering the advantages and disadvantages of each one. Existing GCTB treatments are not 100% safe and effective at the same time. and this is the reason why the search for other treatment modalities should continue to offer a better oncologic and functional outcome to ...

Application of Artificial Intelligence in Breast Medical Imaging Diagnosis

Review Article of American Journal of Cancer Research and Reviews Application of Artificial Intelligence in Breast Medical Imaging Diagnosis Yao Xiao1*, Yiyuan Qu1, Tingting Wu1 1College of Medicine, China Three Gorges University, Yichang, 443002, China. According to the latest report on urban cancer in China published in 2017: China is one of the countries with the fastest growing incidence of breast cancer, and the age of onset has gradually become younger. Newly diagnosed breast cancer patients in China account for 12.2% of new breast cancer patients worldwide, and the mortality rate is 9.6%. A large amount of clinical experience has proven that the survival rate of breast cancer detected at an early stage is significantly higher than that detected at an advanced stage. Imaging examination is an important method for early detection of breast cancer. With the advent of the Artificial Intelligent, the method of AI + medical imaging has been widely used in lungs, breasts, heart, skull, liver, prostate, bones and other parts. Methods used in breast cancer screening include: breast self-examination and clinical physical examination, mammography of mammography of the breast, ultrasound of the breast, and magnetic resonance imaging (MRI) of the breast. The advantages and disadvantages have been reflected in the development and application in recent years. This article will review the advantages and disadvantages of combined diagnosis of AI and breast medicine. It is hoped that the artificial intelligence of medical imaging screening for breast diseases has a brighter and broader prospect. Keywords: Breast; Medical imaging; Artificial intelligence (AI); Advantages and disadvantages ...

Review on breast cancer immunotherapy

Review Article of American Journal of Cancer Research and Reviews Review on breast cancer immunotherapy Selamawit Fentahun Ali School of Veterinary Medicine, Wollo University Cancer immunotherapy consists of approaches that modify the host immune system, and/or the utilization of components of the immune system for treatment and prevention of cancer. Eventhough breast cancer has historically not been considered a favorable target for immunotherapies as compared to those solid tumors such as melanoma and renal cell carcinoma, several preclinical and clinical studies have provided important insights and clinical data that support its potential to improve clinical outcomes for patients with breast cancer. In addition, the recent definition of tumor-specific immunity in breast cancer patients and the identification of several breast cancer antigens has generated enthusiasm for the application of immune based therapies to the treatment of breast malignancies. In general, immunotherapies can be considered either non-specific, such as cytokine, or tumor specific for example a vaccine that targets breast cancer tumor antigens. Current immunotherapeutic approaches either through immunization of the patient (e.g., by administering a cancer vaccine), in which case the patient’s own immune system is trained to recognize tumor cells as targets to be destroyed, or through the administration of therapeutic antibodies as drugs, in which case the patient’s immune system is recruited to destroy tumor cells by the therapeutic antibodies, Cell based immunotherapy is another major entity of cancer immunotherapy. The review concluded that immunotherapeutic approaches combined with novel sequences of chemotherapies, radiation, and immunomodulating agents hold promise for enhancing the treatment of breast cancer. Keywords: immunotherapy, monoclonal antibodies, cytokine, breast cancer, immune system and cancer vaccines ...

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1. Hongmei YANG. A study on the Management Mode of Modern Vocational Education in China. Global journal of Economics and Business Administration, 2018, 3: 10.DOI: 10.28933/gjeba-2018-07-2301 

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fees: We do not charge any submission charges, but authors are required to pay publication fees after their manuscripts are accepted for publication. For authors who receive our invitations, please send us the invitation code to receive the special discount.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly.

Withdrawal Policy: When you want to withdraw an article, please contact us. We will withdraw/retract it from our system after reviewing your request.

Terms of Use/Privacy Policy/Disclaimer/Other Policies: you agree that by using or receiving our services, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies.

About the journal
The journal is hosted by eSciPub LLC. Our aim is to provide a platform that encourages publication of the most recent research and reviews for authors from all countries.

About the publisher
eSciPub LLC is a publisher to support Open Access initiative located in Houston, Texas, USA. It is a member of the largest community of professional publishers in the United States: the Independent Book Publishers Association. It hosts more than 100 Open Access journals in Medicine, Business & Economics, Agriculture, Biological Sciences, Chemistry, Education, Physical Sciences, Sociology, and Engineering and Technology.

Rapid Response Team
Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

American Journal of Cancer Research and Reviews